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COPD is a common disease which is increasing in prevalence. The proportion of patients who
vary their inhaler use from what is prescribed and the reasons for variance are largely
unknown. The objective of this study was to determine the extent of and reported reasons
for patient-reported variance in the use of inhalers prescribed for COPD. A 17-item survey
was mailed to 600 ambulatory patients with spirometry-defined COPD. The survey included
questions about inhaler use and reasons for using inhalers differently than prescribed. Survey
responses were compared between patients reporting no variance vs. variance from prescribed
instructions. Logistic regression was used to determine predictors for variance. The response
rate was 45.8% (48.7% male; mean age: 73  8 years). Forty percent of respondents were
not using inhalers as prescribed. The most common reasons were: feeling the inhalers did
not help breathing (20%), forgetting to use inhalers (19%) and cost (15%). Higher education
level, home oxygen use and prescriptions for ipratropium were predictors for inhaler variance.
The impact of inhaler variance on morbidity of COPD should be evaluated.
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9 Elsevier Ltd. All rights reservedChronic obstructive pulmonary disease (COPD) is a disease
characterized by airflow limitation.1 The incidence of COPD
is increasing and is the fourth leading cause of death in the
United States.2 By 2020, COPD is expected to become the
third most common cause of death worldwide.3
The goals of treating COPD are to prevent disease
progression, relieve symptoms, improve exercise tolerance,
prevent complications, exacerbations and infections, and
reduce mortality. Other than smoking cessation, no clinical
interventions have been shown to modify the long-term.
100 K. VanderSchaaf et al.decline in lung function that is the hallmark of COPD,
although both supplemental oxygen and the influenza
vaccination may prolong survival.1 The Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines provide
recommendations for diagnosing and classifying disease
severity and strategies for treating and monitoring disease
progression.1 Despite the publication of these guidelines,
a significant treatment gap exists in that the disease
remains under-diagnosed and under-treated.4e7
Few studies have evaluated reasons for the treatment
gap, but physician-, health care system-, and patient-
related factors likely all contribute. With regard to patient-
related factors, studies suggest that up to 50% of COPD
patients are non-adherent (i.e., vary inhaler use) to
prescribed therapy.8e14 Non-adherence is defined as the
extent to which a person’s behaviour corresponds with
agreed recommendations from a health care provider.15
Patients may underuse, overuse, or misuse medications.
Underuse is a reduction (whereas overuse is an increase) of
the daily use of medication indicated for the treatment or
prevention of a disease or condition,16 whereas use of an
ineffective, not indicated, or duplicate drug is defined as
misuse.16 Patientsmay also self-manage their COPDbased on
their symptoms.12,13 There are limited data on the extent of
patient-reported variance in inhaler use and reasons for
variance.13 The purpose of this study was to determine the
extent of patient-reported variance to prescribed inhaler
regimens and the reported reasons for this variance in
patients with spirometry-defined COPD.
Materials and methods
Study design and patient population
This was a cross-sectional survey mailed to ambulatory
patients with spirometry-defined COPD at Kaiser Perma-
nente Colorado (KPCO). KPCO is a group-model, closed-
panel, non-profit health maintenance organization that
provides integrated health care services to over 470,000
members at 17 medical offices in the DenvereBoulder
metropolitan area. Medical and pharmacy records were
reviewed for pertinent study-related data for all patients
who responded to the survey. Study approval was obtained
from the KPCO Institutional Review Board.
Patients were identified for study inclusion using a KPCO
database that houses validated patients with spirometry-
defined COPD. This database is populated administratively
using ICD-9 diagnoses codes with patients who have had at
least two encounters with a COPD diagnosis at clinic visits,
emergency department visits, or hospitalizations separated
by at least 30 days. Spirometry-data are then manually
abstracted from medical records for each patient and
classified by severity (mild, moderate, severe and very
severe) based on GOLD guidelines.1 Patients with spirom-
etry-defined COPD per the GOLD guidelines were eligible
for inclusion.1
Survey development and administration
Invitation letters, the survey instrument, and an addressed,
postage-paid envelope were mailed to eligible patients.The invitation letter contained required elements of
informed consent to allow access to the patients’ medical
and pharmacy records. Reminder postcards were sent to
non-respondents 30 days after the original mailing. In order
to protect patient confidentiality, surveys were mailed,
collected, and analyzed by a local, independent research
firm. Responses were collated and entered into a database
that identified patients only by a unique identifier which
was then linked back to medical record numbers by the
researchers.
Searches of the medical literature using the MEDLINE
database (1966 through November 2006) were conducted in
order to retrieve any current literature in which a survey
appropriate for our needs had already been published.
Reference lists of studies were also manually reviewed to
identify any additional relevant studies. Through this
process, one study was identified. Although the survey used
in this study was not validated for construct, it did undergo
a process for face and content validity.13 A 3-page, 17-item
survey (Appendix I) was developed to assess self-reported
inhaler use, patient beliefs about COPD, and demographic
characteristics. The initial survey items were developed by
the study investigators. Initial drafts of the survey were
independently reviewed by five clinical pharmacy special-
ists and two primary care physicians with extensive expe-
rience in developing patient adherence surveys who were
not active participants on the study team. The survey was
revised based upon these comments. The survey was
revised based on the content experts’ feedback.
Patients reported the number of times they used each
inhaler per day on the first section of the survey, we did not
use other types of adherence scales (such as Medication
Adherence Scale or Inhaler Adherence Scale) to limit the
length of the survey. Patients reported reasons for varying
inhalers by selecting responses from a list of possible reasons
or adding reasons in an open-ended fashion. Patient-repor-
ted inhaler use that varied from the prescribed regimen was
ascertained by the question: ‘‘Do you use all your inhalers
exactly as they have been prescribed by your physician?’’
(Answer options were yes or no). A Likert-type scale
(1Z strongly disagree, 5Z strongly agree) was used to
quantify the responses to questions regarding patient
beliefs and understanding about COPD and its treatment.
Responses were dichotomized and compared by strongly
disagree/disagree/neutral vs. agree/strongly agree.
Sample size
No formal sample size was determined for this study because
the primary outcome was descriptive. A convenience sample
of 600 patients with spirometry-defined COPD was surveyed.
After surveying was complete, an analysis for potential non-
response bias was conducted by comparing administratively
available demographic characteristics (age, sex, COPD
severity) of respondents to non-respondents.
Statistical analysis
The primary outcome measure was to describe the
proportion of patients who self-reported varying their
inhaler use compared to how it was prescribed. Secondary
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are not being used as prescribed, and to characterize
patient understanding and beliefs about COPD and
management. All data analyses were performed at KPCO
using the SAS statistical package version 9.1 (SAS Institute
Inc, Cary, NC). Age was reported as a mean and standard
deviation. Proportions were calculated for nominal- and
ordinal-level data (e.g., sex, smoking status, education
level). Interval- level outcome variables were assessed for
normality of their distributions and appropriate tests (e.g.,
t-test, rank-sum test) were used to assess differences in
mean or median values between self-reported inhaler
variance. Differences between cohorts for dichotomous or
continuous outcome variables, including responses to
questionnaire items, were measured using the chi-square
test or t-test, respectively. Multivariate logistic regression
analysis was used to identify independent predictors of
self-reported inhaler variance. Potential predictor vari-
ables included age, sex, COPD severity, medications
prescribed, and responses to survey questions. To preserve
power in the model, survey responses were converted from
ordinal variables to dichotomous variables. For example,
‘‘strongly disagree,’’ ‘‘disagree,’’ and ‘‘neutral’’ responses
were compared to ‘‘agree’’ or ‘‘strongly agree.’’ Non-
significant variables in the model were removed until the
best fitting model was determined, using Akaike’s Infor-
mation Criterion. Statistical significance was set at a two-
sided alpha of 0.05.
Results
Of the 600 surveys mailed, 275 (45.8%) were returned and 10
were not useable because theywere incomplete. TherewereTable 1 Respondent characteristics based on patient-reported
Characteristic Total (nZ 265)
Male, % 48.7
Age, mean (SD), years 73 (8)
COPD severity, %
Mild 8.7
Moderate 47.2
Severe 35.1
Very severe 9.1
Past smoker, % 75.5
Home oxygen use, % 57.4
Education level, %
Did not finish high school 11.0
High school graduate 34.3
Higher education but not college graduate 31.0
College graduate 21.5
Inhaler type, %
Short-acting b-agonist 91.7
Ipratropium 83.0
Inhaled corticosteroid 73.6
Tiotropium 64.2
Long-acting b-agonist 64.5
LABA/ICS 63.8no differences between respondents and non-respondents in
terms of sex, age or COPD severity. The average age of
respondentswas 73 8 years and 48.7%weremale. A total of
40% of respondents reported variance, while the remaining
60% reported not varying their inhaler use from their
prescribed regimen. Table 1 outlines respondent character-
istics in these two groups.
The groups were statistically different in regards to
COPD severity, home oxygen use, and education level
(Table 1). More patients with severe COPD were in the non-
variant group (42.1% vs. 24.5%, pZ 0.02) and a larger
proportion of patients using home oxygen were in the non-
variant group (62.9% vs. 49.1%, pZ 0.03). Patients with
higher education, defined as education beyond high school
with or without an advanced degree, reported more vari-
ance than those with a high school diploma or less educa-
tion (58.5% vs. 41.5%, pZ 0.04). Both groups were similar in
terms of race, general health status, living situation and
income level.
Fig. 1 depicts patient-reported reasons for variance in
inhaler use. The most common reported reasons were:
feeling the inhalers did not help breathing (20%), forgetting
to use the inhalers (19%), and cost (15%). Nine patients
were excluded from this analysis since they were not
prescribed inhalers by their physician and ‘‘not applicable’’
was not included as an answer on the survey.
There were significant differences in responses between
variant and non-variant groups for survey items about
understanding of COPD/medications (Table 2). Patients
who did not vary their inhaler use reported a greater
agreement to the statement ‘‘I have a good understanding
about my lung disease’’ (69.2% vs. 37.7%, p< 0.001) as well
as ‘‘I understand how to manage my lung disease’’ (63.5%variance of inhaler use.
Non-variant (nZ 159) Variant (nZ 106) p-Value
50.9 45.3 0.37
73.2 (8.0) 73.3 (8.2) 0.88
7.6 10.4 0.42
40.9 56.6 0.01
42.1 24.5 <0.01
9.4 8.5 0.79
78.6 70.8 0.14
62.9 49.1 0.03
13.2 7.5 0.15
34.6 34.0 0.92
25.2 39.6 0.01
23.3 18.9 0.39
93.7 88.7 0.15
81.8 84.9 0.50
74.2 72.6 0.78
65.4 62.3 0.60
66.0 62.3 0.53
65.4 61.3 0.50
0% 4% 8% 12% 16% 20%
Physical difficulty with inhalers
Other
Too many doses
Confused about inhalers
Inhalers not needed
Side effects with inhalers
Use inhalers as needed
Cost
Forget to use inhalers
Inhalers do not help breathing
Figure 1 Patient-reported reasons for inhaler variance.
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not vary their inhaler agreed with the statement ‘‘I have
been taught and remember how to use my inhalers’’ (90.5%
vs. 53.8%, p< 0.001).
Logistic regression analysis was performed to identify
independent predictors of patient-reported inhaler vari-
ance while controlling for age, sex, COPD severity, oxygen
use, medications prescribed, and responses to survey
questions. Patients were more likely to report inhaler
variance if they disagreed or had a neutral response to the
statements ‘‘I have been taught and remember how to use
my inhalers’’ (OR 7.9; 95% CI, 3.7e17.0) and ‘‘I understand
how to manage my lung disease’’ (OR 2.4; 95% CI, 1.3e4.5).
Patients were also more like to report varying inhaler use if
they had prescriptions for ipratroprium (OR 2.5; 95% CI,
1.1e5.7), used home oxygen (OR 2.1; 95% CI, 1.1e3.8), or
had higher education (beyond a high school) level (OR 2.1;
95%, CI, 1.1e3.6).Discussion
The results of our study demonstrate that 40% of patients
reported varying their inhaler use. Although the degree of
COPD severity was not an independent predictor ofTable 2 Proportion of patients who strongly agreed/agreed to
Survey item
I have a good understanding about my lung disease
I understand how to manage my lung disease
I would like to learn how to manage my lung disease better
Nothing will help me manage my lung disease better
I have been taught and remember how to use my inhalers
a Data categorized into proportion of patients who strongly agre
disagreed.variance in the logistic regression model, use of home
oxygen, which may be considered a marker for disease
severity, was an independent predictor. The importance of
disease-specific education is underscored by the fact that
patients who did not recall receiving inhaler-education or
did not report a good understanding of how to manage their
disease were more likely to vary inhaler use. The fact that
ipratroprium use predicted inhaler variance could be due to
the difficult dosing schedule of this drug which is typically
administered four times daily, studies have shown that
COPD patients using tiotropium which is administered once
daily were 2e3 times more persistent with use of this
medication compared to patients using other therapies
including ipratropium.17
In this study it was observed that patients with higher
education (beyond high school) were more likely to report
varying their inhaler use, which conflicts with another study
showing better adherence associated with a higher educa-
tion level.18 The difference in findings may be related to
how adherence and variance were defined in the studies.
The study associating higher education with higher adher-
ence measured adherence using the average number of
minutes patients used their nebulizer daily vs. the
prescribed amount, while our study utilized patient self-
report.18 Other studies looking at oral medicationsurvey items.a
Overall Non-variant Variant p-Value
150 (56.6) 110 (68.2) 40 (37.7) <0.001
136 (51.3) 101 (63.5) 35 (33.0) <0.001
154 (58.1) 98 (61.6) 56 (52.8) 0.15
38 (14.3) 27 (17.0) 11 (10.4) 0.13
200 (75.8) 143 (90.5) 57 (53.8) <0.001
ed/agreed and those who were neutral, disagreed or strongly
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level and adherence.19,20 It is unknown why education level
was related to inhaler variance in our study but it is possible
that more educated patients may be more willing to report
variance. Further studies evaluating this finding should be
explored.
Few prior studies describe patient-reported variance
with inhalers for COPD. One study used a 3-item ques-
tionnaire administered by a physician to evaluate inhaler
adherence in 185 patients with chronic airflow obstruc-
tion defined as chronic bronchitis or emphysema. Patients
were compared based on whether they were fully
adherent (i.e., took prescribed therapy regularly and
adjusted therapy during exacerbations, as advised) vs.
adherent with maintenance therapy only (i.e., took
prescribed therapy regularly).9 The study reported that
only 47% of patients with chronic airflow obstruction were
adherent with their maintenance therapy.9 Another
survey of 117 community-dwelling patients (74% with
COPD) assessed whether patients were using their nebu-
lizers as prescribed. This study used a mailed survey
asking patients to report how often they used their
nebulizers.10 The investigators found that less than half
of the patients with COPD used their nebulizer as
prescribed. Although these studies used different
methods for assessing variance with inhaled medications,
the results are consistent with ours in that about 40e50%
of patients with COPD do not use inhalers or nebulizers as
prescribed.
While the aforementioned studies assessed prevalence
of patient-reported variance, they did not determine
predictors of variance or reasons for varying inhaler use.
Examining reasons patients misuse their inhalers is
important for designing and implementing appropriate
interventions to improve outcomes. One study of 78
outpatients with COPD found that 42 (54%) underutilized
their inhalers.12 Adherence was measured using two 6-
item self-report scales, the medication adherence scale
(MAS) and inhaler adherence scale (IAS). The most
common reason for patients reporting poor adherence
was attributed to ‘‘feeling good and deciding not to
dose’’.12 Adherence was also observed to change based
on the type of medication patients were receiving, the
use of anticholinergics was associated with worst patient
adherence. More recently, George et al. investigated
predictors of medication adherence in 276 outpatients
with COPD using a 30-item questionnaire and the medi-
cation adherence report scale (MARS).13 Health beliefs,
experiences, and behaviors were compared in patients
with COPD who self-reported good adherence (37%) to
those who self-reported suboptimal adherence (63%) to
their medications. Independent predictors of non-adher-
ence were ‘‘I vary my recommended management based
on how I am feeling’’ and ‘‘I get confused about my
medications’’. Patients self-reporting good adherence had
better understanding of their lung disease, were less
likely to use natural remedies, and had more faith in
their doctors.13
There are likely numerous reasons why patients with
COPD vary inhaler use. In our study, the most common
self-reported reasons were due to feeling the inhalers did
not help breathing, forgetting to use the inhalers, and thecost of the prescription(s) which are similar to other
findings in COPD literature12,14 One study found that more
patients who were non-adherent to their nebulizer noticed
no difference in their breathing compared to adherent
patients.14 Another study reported up to 50% of patients
non-adherent to their inhalers forgot to use their inhalers,
8.9% believed the medications were ineffective, and 3.8%
had cost constraints.12 If patients are using certain
inhalers to relieve symptoms, when in fact they are meant
to prevent exacerbations, it is likely that patients will feel
the inhalers are not working properly. Patients must
receive proper education regarding the purpose of each
inhaler. Prescribing simple dosing schedules may also help
patients remember to use the inhalers as they are inten-
ded. Cost is another important consideration.21,22
Prescribers should continue efforts to use the most cost-
effective inhalers or explore financial assistance for
patients, where applicable.
Our study is not without limitations. We had just less
than a 50% response rate, which is similar to other surveys
in patients with COPD.9e13 The survey used for this study
was not validated, however many of the items utilized were
similar as those used in other surveys.13 The definition of
variance in our study was based on patient self-report.
Patient self-report was felt to be a quick and simple
method to evaluate medication variance given the diffi-
culty in assessing adherence with inhalers using objective
measures such as pharmacy administrative data or elec-
tronic monitoring. Some studies support patient self-report
as a good predictor of adherence while others have shown it
is not an accurate report.23 Patients may over-report
medication/inhaler use when asked to self-report but on
the other hand, patients who admit non-adherence are
usually correct.24 We did not correlate patient-reported
variance to outcomes such as hospitalizations, quality of
life, or exacerbations. Furthermore, we did not evaluate
economic outcomes which may have been associated with
inhaler variance.
The impact of periodic monitoring and follow-up of
patients with COPD on inhaler variance could be evalu-
ated. Future steps to help increase awareness and improve
the management of COPD may be implementation and
evaluation of an educational intervention aimed to make
patients more knowledgeable about COPD, including
proper inhaler use. This study demonstrates that 40% of
patients with COPD do not use their inhalers in accordance
to prescribed instructions. Further investigation on inhaler
variance and how it relates to morbidity of COPD is
merited.Conflict of interest statement
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Appendix I. Survey.
Please answer the following questions the best you can. There are no right or 
wrong answers.
Please check the box beneath the column that best describes how often you 
currently use each of the following inhalers. 
Never Most but 
not every 
day
1-2
times
per day
3 or more 
times per
day
Albuterol (Proventil®, Ventolin®-total 
doses of inhaler and/or nebulizer)
Ipratriopium (Atrovent®-total doses of 
inhaler and/or nebulizer)
Tiotropium (Spiriva®)
Salmeterol (Serevent®)
Fluticasone/Salmeterol combination 
(Advair®)
Any inhaled steroid (fluticasone, 
mometasone, budesonide, QVAR®, 
Flovent®, Asmanex®)
Other, (please list):
1. Do you use all your inhalers exactly as they have been prescribed by your 
physician?
Yes
No, Why? (check all that apply)
Costs too much to get them all filled
I have physical difficulty using my inhalers
The inhalers give me side effects
The inhalers do not help my breathing
I get confused about which inhaler to use
I forget to use them all
The number of doses prescribed per day is hard to fit in
Other_____________________________
2. Do you use ox ygen at home?
Yes No
3. What is your smoking status (cigarettes or pipes )?
Never smoke d      
Current ly smoke, how many packs per day? _ __________    
Past smoke r
    How ma ny years ago did yo u quit? ___ _____
4. How would you rate  your general health?
  Excellent
  Very good
  Good
  Fair
  Poor
  Don’t kn ow/not sure
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5. What is the highest grade or level of school that you have completed?
Did not finish high school     
High school graduate    
Some college     
College graduate
6. Which of the following best describes your race and/or ethnicity (check all
that apply)?
White or Caucasian
Black or African-American
Asian or Pacific Islander
American Indian/Alaskan Native
Hispanic / Latino
Other:___________________
7. What is your current living situation?
Live alone
Live alone with assistance  
Live with someone
Other:__________
8. Which category best reflects your annual household income?
Less than $35,000
$35,000 to $75,000
$75,000 and over
I don’t know
I choose not to answer
Inhaler use in COPD
To what extent do you agree or disagree with the following statements?
Strongly
disagree
Disagree Neutral Agree Strongly
Agree
Doesn’t
Apply
I vary the way I use my inhalers 
depending on how I feel
I have a good understanding about my 
lung disease
I understand how to manage my lung 
disease
I would like to learn how to manage my 
lung disease better 
Nothing will help me manage my lung 
disease  better
I have been taught and remember how 
to use my inhalers 
I would like more information on managing my lung disease
Yes No
I would like to get this information in the following ways (check all that apply)
__ A class about my lung disease and medications
__ A class on smoking cessation
__ Written information about my lung disease and/or medications
__ On-line resources about my lung disease and/or medications
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